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1. Introduction 
1.1 Atherosclerosis & cholesterol 
The link between cardiovascular disease (CVD) and lipids has been appreciated for a long 
time, but the individual role of specific lipids in predisposition to disease is constantly 
under question. Cardiovascular disease, including myocardial infarction (MI), heart failure, 
and stroke, represents the leading cause of mortality worldwide, accounting for half of the 
total number of deaths in the developed world (World Health Organization, 2002). CVD will 
result in 20.5 million deaths annually by 2020 (World Health Organization, 2002, Fig. 1), 
(Revkin et al. 2007). 
 
Fig. 1. Cardiovascular disease accounts for one third of deaths worldwide and half of deaths 
in the developed world. Data from World Health Organization (2002). 
Atherosclerosis, or "athero" as we call it, is a condition underlying most cardiovascular 
diseases (Berliner et al. 1995) and results from an imbalance between uptake and efflux of 
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cholesterol by macrophages in the wall of blood vessels. It is the progressive buildup of 
plaque in the arteries over time causing narrowing of the vessels and severely limiting blood 
flow in advanced cases. Rupture of the plaque and thrombosis may result in complete 
occlusion of the vessel and, ultimately, myocardial infarction or stroke (Berliner and Glass). 
For many of us, this plaque starts building up in our arteries in early adulthood and gets 
worse over time (Fig.2, for illustrative purposes). 
 
Fig. 2. Atherosclerosis; the progressive build up of plaque in arteries over time. 
Cholesterol  
Is a fatty substance, also called a lipid, which is produced by the liver. It is also found in 
foods high in saturated fat, like fatty meats, egg yolks, shellfish, and whole-milk dairy 
products. Since lipids are insoluble in blood, they are carried in association with proteins as 
lipoproteins, which allows their transport around the body. Lipoprotein complexes present 
in the serum have been the focus of much study in the etiology of cardiovascular disease 
(Goldstein, 1990).  
There are five types of lipoproteins, and this classification is based on their densities. Those of 
lowest density, the chylomicrons, contain more lipids and less protein than those at the other 
extreme, high-density lipoproteins (HDLs). Between these classes are the very low-density 
lipoproteins (VLDLs), low-density lipoproteins (LDLs), and intermediate-density lipoproteins 
(IDLs). Plasma cholesterol is carried from the intestine and the liver to peripheral tissues 
largely in the form of LDLs. Most clinical studies concentrate on the relative abundance of 
HDLs and LDLs in the serum. LDL cholesterol is considered "bad" because too much of it in 
the blood stream can contribute to the progression of atherosclerosis, the buildup of plaque in 
the arteries. HDL cholesterol, on the other hand, is considered "good", it appears to be 
protective against cardiovascular disease (Miller, 2000), and this is generally considered to be 
due to the efficiency by which HDL returns cholesterol to the liver for metabolism and 
excretion, resulting in reduced serum cholesterol availability (Barter & Rye, 1994).  
The elevated levels of the lipoprotein (LDL) and (VLDL) are usually associated with atheroma 
formation. Therefore, defects in cholesterol metabolism are a major cause of cardiovascular 
disease, this is apparent in patients with familial hypercholesterolemia, characterized by 
grossly elevated levels of serum cholesterol, in particular LDL. Reduction of plasma LDL-
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cholesterol (in patients with elevated levels) is associated with a decreased incidence of 
coronary  heart disease (CHD) (Anderson; Boden; Farnier; Fruchart and Gordon). Also, there is 
an increasing evidence that serum triglycerides (TGs) are strong risk factors in cardiovascular 
disease in many patients with  normal circulating LDL-cholesterol, but with  high levels of 
plasma TGs and concomitantly low levels of HDL-cholesterol (Cullen; Krauss and Rubins). 
LDL-cholesterol has been well established as an independent risk factor since reporting of 
the 1948 Framingham study (Gordon et al. 1977). HDL-cholesterol is recognized as being a 
negative risk factor for CHD (Fruchart et al. 1998). While LDL cholesterol is a major health 
factor, here are a few other factors that can contribute to the progression of athero. 
 Family history of early heart disease  
 Diabetes  
 High blood pressure  
 Cigarette smoking  
 Overweight/obesity  
In a prospective follow-up study of 56 individuals with known CVD, a relationship between 
progression of atherosclerosis in the left main coronary artery and coronary risk factors was 
demonstrated (von Birgelen et al. 2004) (Fig. 3). In this study, the investigators  applied three 
different, commonly used cardiovascular risk scores to subjects (Anderson et al. 1991 & 
Assmann et al. 2002, and Conroy et al. 2003) and demonstrated a positive linear relationships 
between the calculated risk of CVD and plaque progression (Revkin et al. 2007). 
 
Fig. 3. Relationships between cardiovascular risk factors and atherosclerosis   progression in 
the left main coronary artery. Data from von Birgelen et al. (2004). Reprinted from 
Circulation 110:1579–1585. 
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2. Biomarkers of atherosclerosis 
Atherosclerosis as a disease characterized by low-level vascular inflammation is gaining much 
attention recently. Some lipid parameters i.e. total serum cholesterol TC, LDL cholesterol, HDL 
cholesterol and triglyceride contents and also, serum markers of inflammation are considered 
as predictive biomarker for the prevalence of atherosclerotic disease.  
Biomarkers: A biomarker is defined as a characteristic that is objectively measured and 
evaluated as an indicator of normal biologic or pathogenic processes or as physiologic 
response to a therapeutic intervention. In clinical medicine, biomarkers are routinely used in 
disease diagnosis, prognostication, ongoing clinical decision-making, and follow-up to 
assess effects of therapy.  
 Commonly used biomarkers: e.g. electrocardiogram, isotopic and ultrasound imaging 
studies applied in multiple areas of disease management, bone densitometry in the 
assessment of osteoporotic fracture risk. 
  Commonly used soluble biomarkers include low- and high-density lipoprotein 
cholesterol (LDL-C and HDL-C), triglycerides (TG), serum creatinine, and 
hepatocellular enzymes, as well as a host of other routine clinical laboratory 
measurements. 
 Surrogate endpoints are biomarkers that are predictors of clinical outcomes.. Typical 
surrogate endpoints used to assess the clinical efficacy of cardiovascular drugs include 
levels of LDL-C and blood pressure.  
The need for more rapid drug development highlights the role that surrogate markers may 
play in establishing the efficacy of drugs for managing CVD, and more specifically, 
atherosclerosis (Revkin et al. 2007). 
a. Lipid markers of atherosclerosis:  
Plasma levels of lipids and lipoproteins have been well established as strong predictors of 
CHD. There is, also, a stronger positive correlation of apolipoproteins (apo) with 
atherosclerosis and coronary events than that of the plasma lipoproteins, either cholesterol 
carried by lipoprotein particles or their actual concentration expressed as apo B and apo A-I.  
Lipoproteins are spherical molecules that transport different amounts of cholesterol and 
triglycerides in the blood stream. LDL and HDL particles are rich in cholesterol, while 
VLDL and chylomicron particles predominantly transport triglycerides The apo B is present 
on the surface of LDL, VLDL and chylomicrons (one molecule at each particle), while apo A-
I resides on HDL particles (Fig.4). Lipoprotein (a) consist of two main components: low-
density lipoprotein (LDL) and apolipoprotein (apo) (a) linked by a single disulphide bond 
between the C terminal of apo B100 and apo(a) kringle (K) IV type 9.The LDL particles  may 
differ among individuals in the cholesteryl ester content of the lipid core that is surrounded 
by a monolayer of phospholipids, unesterified  cholesterol, and apo B100. Apo (a) is made of 
10 different type IV kringles (1-10) followed by kringleV and a catalytically inactive protease 
domain (P), (Angelo M. et al. 2008). 
Conventional lipid tests determine the amount of cholesterol and triglycerides transported 
by all particles within the lipoprotein classes or in total plasma. Thus, cholesterol and 
triglycerides may be regarded as surrogate markers for their carrier-lipoprotein particles.  
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Fig. 4. Schematic representation of lipoprotein (a).  
The level of apoB-containing lipoprotein particles is measured directly, mostly by 
immunonephelometric analysis of the plasma, on empty stomach or postprandially, 
whereas LDL cholesterol is mostly calculated indirectly as the difference of total cholesterol 
minus HDL-cholesterol and VLDL-cholesterol. In that respect, apo B can be considered a 
superior indicator of the global atherogenic risk over the sole quantification of LDL 
cholesterol and triglyceride levels, particularly in conditions of hypertriglyceridaemia 
characterized by high VLDL and low LDL levels. (JMB 2008, 27:148 –153). 
Non-HDL cholesterol: Another approach to the measurement of atherogenic lipoproteins is 
the use Non-HDL cholesterol which is easily calculated by deducting the HDL cholesterol 
from the total cholesterol value, with no need for previous fasting of the patient. This is the 
cholesterol contained in VLDL and LDL particles, atherogenic triglyceride-rich lipoproteins, 
cholesteryl ester-enriched remnants of triglyceride-rich lipoproteins, and lipoprotein(a). 
Consequently, the non-HDL cholesterol is essentially the cholesterol analogue to an apo B 
level. The non-HDL cholesterol content is easily available within the primary screening of 
the lipid profile, and according to the recommendations of NCEP ATP III it is identified as a 
secondary therapeutic target after achieving the target levels of LDL cholesterol. (JMB, 2008, 
27:148 –153). 
b. Circulating markers of inflammation and atherosclerosis: 
Epidemiologic and prospective studies evaluating the predictive value of the variety of 
circulating markers of vascular inflammation  such as C-reactive protein (CRP), fibrinogen, 
serum amyloid A (SAA), leukocyte count in peripheral blood, immunoglobulin, adhesion 
molecules, cytokines and chemokines has been well established. Population studies 
demonstrated a moderate elevation of serum fibrinogen and leukocyte count in peripheral 
blood in individuals subsequently developed atherosclerotic disease. Increased fibrinogen 
levels were identified as strong predictors of stroke (JMB, 2008, 27:148 –153). 
3. Metabolic syndrome 
The metabolic syndrome has emerged in recent years as a major public health concern. By 
2002 it was estimated that as many as 24% of American adults suffer from the metabolic 
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syndrome as defined by the ATPIII criteria*).Individuals suffer from the metabolic 
syndrome have been demonstrated to be at increased risk of the development of 
hypertension, atherosclerosis, type II diabetes and cardiovascular disease. The term 
‘metabolic syndrome’ refers to a cluster of metabolic abnormalities associated primarily 
with obesity including elevated plasma triglycerides (TG), low-density lipoprotein (LDL-
cholesterol), and very low-density lipoprotein (VLDL-cholesterol), reduced high-density 
lipoprotein (HDL-cholesterol), and elevations in blood pressure and fasting glucose.  
4. Dyslipidemia 
Dyslipidemia is a disruption in the amount of lipids in the blood either by increase or decrease. 
Most dyslipidemias are hyperlipidemias; that is, an elevation of lipids in the blood, often due 
to diet and lifestyle. The increased type of dyslipidemia could be differentiated as:   
 Hyperlipidemia: increase in lipids; either increase in cholesterol (Hypercholesterolemia), 
in glycerides (Hyperglyceridemia) or in triglycerides (Hypertriglyceridemia).  
 Hyperlipoproteinemia: increase in lipoproteins (usually LDL).  
 Combined hyperlipidemia: that is an increase in both LDL and triglycerides. 
*Executive Summary of the Third Report of the National Cholesterol Education Program 
(NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In 
Adults (Adult Treatment Panel III; ATPIII) 2001, JAMA 285: 2486–97 
5. Managing cholesterol 
The elevated levels of the lipoprotein (high cholesterol level) may depend on the lifestyle of 
the patient. Eating a lot of fats and not getting enough exercise can cause cholesterol levels 
to rise. It's also, in part, a result of the genetic makeup. Some people inherit genes associated 
with elevated levels of cholesterol. One type is called familial hypercholesterolemia. People 
with this genetic makeup can eat a healthy diet and exercise, and still have high cholesterol. 
Managing high cholesterol may be different for one patient to another depending on the 
medical history and the health of the patient. Therefore, cholesterol test, also known as a 
fasting lipid profile, and, along with complete medical background can work together to 
manage cholesterol.  
6. Cholesterol guidelines 
National Cholesterol Education Program (NCEP) guidelines recommend that all adults over 
age 20 have their cholesterol checked at least once every 5 years. The guidelines below give 
a better idea of where the cholesterol numbers of any person should be. 
Total cholesterol level 
 Less than 200 mg/dL  Desirable 
 200-239 mg/dL  Borderline high 
 240 mg/dL or higher  High 
Total cholesterol is based on your LDL cholesterol (LDL-C) and HDL cholesterol (HDL-C) 
counts. Generally, a lower number is better. 
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Triglycerides 
 Less than 150 mg/dL  Normal 
 150-199 mg/dL  Borderline high 
 200-499 mg/dL  High 
 500 mg/dL or higher  Very high 
Triglycerides, like cholesterol, are another substance that can be dangerous to your health. 
Like LDL-C, you want to keep your triglycerides low.  
LDL-C 
 Less than 100 mg/dL  Optimal 
 100-129 mg/dL  Near optimal /above optimal 
 130-159 mg/dL  Borderline high 
 160-189 mg/dL  High 
 190 mg/dL or higher  Very high 
LDL-C is considered the "bad" cholesterol because if you have too much LDL-C in your 
bloodstream, it can lead to the buildup of plaque in your arteries known as atherosclerosis. 
Generally, lower is better.  
HDL-C 
 60 mg/dL or higher  High 
 Less than 40 mg/dL  Low 
HDL-C is considered the "good" cholesterol because it helps return cholesterol to the liver, 
where it can be eliminated from the body. Generally, higher is better.  
Source: National Cholesterol Education Program (NCEP), Webmed October 27, 2008 
7. Peroxisome proliferator-activated receptor agonists 
Peroxisome proliferator-activated receptors (PPARs) are a group of nuclear hormone 
receptors which function as transcription factors in the regulation of genes involved in 
glucose and lipid fatty acid metabolism and vessel wall function. Three PPAR subtypes 
have been identified: PPAR α,  and ǅ.  
PPARα is predominantly expressed in catabolically active tissues such as liver, heart, 
kidney, and muscle. It is involved in the uptake and oxidation of fatty acids as well as in 
lipoprotein metabolism. PPAR is mainly expressed in adipose tissue and regulates 
insulin sensitivity, glucose and fatty acid utilization as well as adipocyte differentiation 
(Hao Zhang et al. 2009). Recent studies have found that PPARǅ is also a regulator of 
serum lipids  
There are many clinically useful drugs that produce their effects by acting on these 
receptors. The clinically used PPARα agonists are the fibrate class of drugs (including 
Fenofibrate and Gemfibrozil), which elevate HDL cholesterol levels and lower triglyceride 
and LDL cholesterol levels. Fibrate drugs are ligands for the fatty acid receptor PPARα 
(Fruchart  et al. 1999).  
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The clinically used PPAR  agonists comprise the thiazolidinedione (TZD); class of anti-
diabetic drugs. The thiazolidinediones (TZDs) drugs are PPARǄ ligands and these have 
beneficial effects on serum lipids in diabetic patients. The fibrate class of drugs is agonists of 
the PPARα isoform, and the thiazolidinediones (TZDs) that activate PPARǄ isoform. This is 
an area of great pharmaceutical interest concernining the dual α/Ǆ agonists, which have the 
potential to combine the benefits of the fibrates and the TZDs, are under development 
(Helen V. et al. 2002). 
It has been hypothesized that the combination of PPAR and PPARα agonist activities in a 
single compound would result in synergistic improvements in insulin sensitivity and 
normalization of glucose metabolism as well as amelioration of the dyslipidemia associated 
with type 2 diabetes.  
Currently marketed drugs targeting PPAR like rosiglitazone  used for the treatment of type 
2 diabetes. We have recently reported the design and synthesis of Muraglitazar a dual 
PPARα/ agonist which has shown excellent efficacy in animal models of type 2 diabetes 
and the associated dyslipidemia as well as in human clinical trial  ( Fig. 5),  (Xiang-Yang Ye  
et al. 2008). 
   
Fig. 5. Structure of PPAR agonists. 
8. The antiatherosclerotic activity 
The antiatherosclerotic activity is exerted via both cholesterol lowering and direct ACAT 
inhibition in plaque macrophages.  
Acyl-CoA: cholesterol acyl transferase (ACAT) catalyzes the intracellular formation of 
cholesteryl esters (CE) in all mammalian cells. It has been implicated as a key enzyme 
involved in cholesterol absorption, very low density lipoprotein secretion, and the 
formation of lipid-laden macrophages. The accumulation of CE in macrophage-derived 
foam cells is characteristic of the early step in the development of atherosclerosis. ACAT 
inhibitors reduced TC levels without affecting HDL-C. This  can be attributed to decreased 
intestinal cholesterol absorption based on binding to bile acid (Turley SD. and  Herndon 
MW. 1994) 
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Fig. 6. Chemical structure of ACAT inhibitor CS-505 (pactimibe sulfate) & CI-
1011(avasimibe). 
Cholesterol esters (CE) are the main lipid components responsible for the development of 
atherosclerosis; hence they are present in the foam cells and extracellular plaque matrix, and 
susceptible to oxidation that could increase their atherogenic potential.  
The treatment using novel ACAT inhibitor pactimibe sulfate (CS-505), avasimibe (CI-1011) 
(Fig.6), and a potent bile acid binding resin cholestyramine directly affects macrophages in 
atherosclerotic lesions. They would limit the increase in intracellular free cholesterol by its 
TC-lowering effect. This would allow free cholesterol to excrete into HDL, restoring the 
cholesterol influx/efflux balance, thus preventing foam cell formation. (Terasak N. et al. 
2007).  
Lipid lowering drugs (LLD) 
Lipid-lowering drugs (LLD) or agents are a diverse group of pharmaceuticals that are used 
in the treatment of hyperlipidemia; some may lower "bad cholesterol" (LDL) more so than 
others, while others may prudentially increase (HDL), "the good cholesterol". Other studies 
showed that elevating the high-density lipoprotein (HDL), as well as, lowering the low-
density lipoprotein (LDL) and triglyceride levels (TGs) in the serum are accepted measures 
in treating hyperlipidemia and atherosclerosis.  
1. Clinical trials 
The lipid lowering in hyperlipidemia is achieved clinically using statins and fibrate drugs. 
Since 1966, there have been 16 major trials investigating the efficacy of statin  and  fibrate 
therapy, both as a single drug treatment and as part of a multi-drug regimen (Napoli C. et 
al. 1997). These trials have involved the participation of some 30,000 patients, and have 
considered both primary and secondary prevention of coronary heart disease (CHD), 
myocardial infarction, stroke, and peripheral artery disease (Tylor, Faergeman, Boden). 
Studies by Nagao et al. (1998), involved the use of fibrate gemfibrozil to reduce cholesterol 
levels in hypercholesterolemia rats fed a cholesterol rich diet.  
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Other studies have confirmed these results (Bruckert and Rustemeijer), while some trials 
involving  gemfibrozil,  bezafibrate,  and  fenofibrate indicated that fibrates can reduce LDL-
cholesterol to a degree comparable with that observed with statins (Feussner; Guay and 
Haffner). Most of the studies are of the general conclusion that statins are the drug of choice 
where the major dyslipidaemia is high-baseline LDL-cholesterol and that fibrates are 
particularly effective in the case of hypertriglyceridaemia (Farnier M. 1998). Other studies 
have confirmed these results while some trials involving bezafibrate, gemfibrozil, and 
fenofibrate indicated that fibrates can reduce LDL-cholesterol to a degree comparable with 
that observed with statins (Guay DR. 1999). 
2. The well-established lipid lowering drugs 
1. Statins: Current ATPIII guidelines for the treatment of patients with the metabolic 
syndrome encourage therapies that lower LDL-cholesterol and TG, and raise HDL-
cholesterol. Primary intervention often involves treatment with statins to improve the 
lipid profiles of these patients. Statins act by competitively inhibiting 3-hydroxy-3-
methylglutaryl-coenzyme A, (HMG-CoA) reductase, the rate-limiting enzyme in the 
cholesterol biosynthesis pathway in the liver (Fig.7), thus stimulates the LDL-receptors 
resulting in an increased clearance of LDL from the blood stream and a decrease in 
blood cholesterol levels. The first result can be seen after one week of use and the effect 
is maximal after four to six weeks. Statins are particularly well suited for lowering LDL 
in people at risk for cardiovascular diseases because of hypercholesterolemia . 
 
(1) 
Lovastatin, the first statin to be marked 
Statins are Lovastatin (1), Mevastatin -naturally-occurring compound found in red yeast 
rice, and Pravstatin. Statins exhibit action beyond lipid-lowering activity in the prevention 
of atherosclerosis;  i) Improving endothelial function  ii) Modulate inflammatory responses , 
iii) Maintain plaque stability, and iv) Prevent thrombus formation. 
Rosuvastatin is a new member of the statin family with higher efficacy in reducing LDL 
cholesterol than other statins at comparable doses . Rosuvastatin has been shown to have an 
increased number of binding interactions with HMG-CoA reductase, compared to other 
statins. rosuvastatin also possesses a relatively long half-life and a high degree of selectivity 
for liver cells (the main site of cholesterol synthesis) compared with non-hepatic cells. 
Rosuvastatin (10 mg) has been shown to improve dyslipidemia in patients with the 
metabolic syndrome (Naples M. et al. 2008). 
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Fig. 7. Synthesis of Cholesterol through HMG-CoA reductase pathway. 
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2. Fibrates: Although fibrates ( e,g. clofibrate 2) are used clinically since the early 1970s, 
the mechanism of action of fibrates remained unelucidated until, in the 1990s, it was 
discovered that fibrates activate PPAR (peroxisome proliferator-activated receptors), 
especially PPARα. The PPARs are a class of intracellular receptors that modulate 
carbohydrate, fat metabolism and adipose tissue differentiation (Staels B. 1998) ; 
(Fruchart  JC. et al. 1999). They typically lower triglyceride by 20% to 25%. The newer 
generation fibrates: gemfibrozil (3) Bezafibrate (4) (Spieker LE. et al. 2000), and 
Fenofibrate (5) afford significant protection from CHD; this might be due to the 
agonistic effect of PPARα that inhibits inflammatory responses at the level of the 
vascular wall. Finally, evidence that fibrates are able to reduce levels of plasma 
fibrinogen, which, in turn, reduces the likelihood of thrombogenesis (Helen et.al. 
2002).  
 
Clofibrate (2) 
Ethyl 2-(4-chlorophenoxy)-2-
methylpropanoic acid 
Gemfibrozil (3) 
5-(2,5-dimethylphenoxy)-2,2-
dimethylpentatonic acid 
              
Bezafibrate (4) 
2-[4-[2-[(4-chlorobenzoyl)amino] 
ethyl]phenoxy]-2-methylpropanoic acid 
Fenofibrate (5) 
Isopropyl 2-[4-(4-chlorobenzoyl) phenoxy]-
2-methyl propanoate 
O
H O
O
Cl O
O
O
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3. Niacin: 3-pyridinecarboxylic acid . also know as  nicotinic acid or vitamin B3, the name 
niacin was derived from nicotinic acid + vitamin, it is also referred to as "vitamin PP", a 
name derived from the absolute term "pellagra-preventing factor". Over the years, 
niacin has gained recognition as an atheroprotective agent, in part because of its 
capacity to lower the plasma levels of cholesterol, triglycerides by 20- 50%., and very-
low- and low-density lipoproteins. It may lower LDL by 5-25% and to substantially 
raise high-density lipoprotein. by 15-33%..In high doses, niacin has also been reported 
to lower the plasma level of lipoprotein(a)  (Angelo M. 2008). 
          N
COOH
N
CONH2
 
Niacin (6) 
 3-pyridinecarboxylic acid 
Nicotinamide (7)  
3-pyridinecarboxamide 
4. Ezetimibe: (Zetia) is a selective inhibitor of dietary cholesterol absorption. In addition 
to this decreased cholesterol absorption leads to an increase in LDL-cholesterol uptake 
into cells, thus decreasing levels in the blood plasma (Rossi S, 2006). 
 
Ezetimibe (8)  
(3R, 4S)-1-(4-fluorophenyl)-3- ((3S)-3-(4-fluorophenyl)- 
3-hydroxypropyl)-4-(4-hydroxyphenyl)-2-azetidinone 
5. Bile acid sequestrants: e.g. Colesevelam hydrochloride (WelChol -- Sankyo) is a 
nonabsorbed, polymeric, lipid-lowering agent that binds with bile acids in the intestine 
and significantly reduces their reabsorption. As the bile acid pool becomes depleted, 
there is an increased conversion of cholesterol to bile acids, thereby reducing cholesterol 
concentrations. The mechanism of action of colesevelam is similar to that of 
cholestyramine (e.g., Questran) and colestipol (Colestid). However, the new drug has a 
greater binding affinity for bile acids, permitting the use of a lower dosage, and appears 
to have a lower incidence of gastrointestinal (GI) adverse events and a lower potential 
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for drug interactions. Colesevelam is indicated for use, alone or in combination with a 
hydroxymethyl-glutaryl-coenzyme A (HMG-CoA) reductase inhibitor (a "statin"), as 
adjunctive therapy to diet and exercise for the reduction of elevated low-density 
lipoprotein cholesterol (LDL-C) in patients with primary hypercholesterolemia 
(Fredrickson Type IIa). In the clinical studies, colesevelam reduced LDL-C 
concentrations by 15% to 18%, and increased high-density lipoprotein cholesterol 
(HDL-C) concentrations by 3%. There were small increases in triglyceride 
concentrations, but these were not statistically different from the results in those 
receiving placebo. 
6. Phytosterols: have cholesterol-lowering properties; reducing cholesterol absorption in 
intestines, and may act in cancer prevention. Phytosterols naturally occur in small 
amount in vegetable oils, especially soybean oil. Sterols can reduce cholesterol in 
human subjects by up to 15% (Rossi S, 2006). 
 
 
 
Ergosterol (9) β-Sitosterol (10) 
7. Thiazolidinediones: TZDs are now seen to fight several aspects of metabolic disease 
within Type II diabetes. They reduce blood glucose while enhancing insulin sensitivity, 
and also have a profound effect on lipid metabolism. Patients with Type II diabetes 
commonly present with elevated plasma levels of TGs and low HDLs. TZDs increase 
TG lipolysis in VLDLs, reducing the level of TGs and increasing HDLs. TZDs increase 
TG lipolysis in VLDLs, reducing the level of TGs and increasing HDLs and have also 
been shown to inhibit the progression of atherosclerosis in animal models (Schoonjans 
& Auwerx, 2000).  
The mechanism of thiazolidinediones (TZDs) drugs by which the change in serum lipid 
profile occurs is not clear, but may involve increases in serum lipoprotein lipase and 
increased lipid uptake by adipocytes and skeletal muscle (Burant and Park). It is also 
possible that it results from direct effects of the drug acting on PPARα (Smith, 2001). It is not 
clear, especially in humans, if PPARǄ promotes lipid clearance in the liver in a manner 
similar to PPARα. 
9. Synthetic hypolipidemic agents 
A continued research effort has been underway over the past several years in the area of  
the development of hypolipidemic agents (Chapman JM. et al. 1979&,1983  & Wyrick SD.  
et al. 1984).  
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Chapman and co-workers initially reported the hypolipidemic activity of phthalimides and 
N-substituted phthalimides  including alkyl, methyl ketone, carboxylic acids, and acetate 
esters of varying chain length  were synthesized and tested for  hypolipidemic activity in 
mice, compounds (1), (2), and (3) were found to afford  the most significant reduction in 
serum cholesterol and triglyceride levels. Phthalimides, the parent compound, decreased 
serum cholesterol and triglyceride levels by 43% and 56% respectively, in mice after 16 days 
of dosing at an optimum dose of 20mg/kg/day (Chapman JM. et al. 1979) 
 
 
 
 
NO O
C4H9
NO O
C2H4COOH C2H4COCH3
NO O
 
 
 
(1) (2) (3) 
 
 
 
 
The hypolipidemic effects of aromatic versus non aromatic imides were investigated. Thus, 
a number of N-substituted phthalimides (4),1,8-naphthalimide (5), succinimide (6), and 
glutarimide (7) derivatives demonstrated significant hypolipidemic activity at 20 
mg/kg/day in male mice (25gm) after16 days of intrapretonially dosing. The dose of 20 
mg/kg/day was selected for structure activity relationship SAR study because this dose 
proved to be the optimum dose when testing phthalimides and 3-N-(1,8-
naphthalimide)propionic acid. Most of the derivatives at 20mg/kg/day demonstrated 
improved activity over clofibrate at 150mg/kg/day. In general, 1,8-naphthalimide and 
glutarimide derivatives appeared to be less active than phthalimides and succinimide. 
Removal of phenyl ring of phthalimides resulting in succinimide led to less hypolipidemic 
activity in general. The loss of aromatic system of 1,8-naphthalimide resulting in glutarimide 
led to a slight loss of anticholesterolemic activity and only α-phenylglutarimide show slight 
improvement of antitriglyceridemic activity (Chapman JM. et al. 1984). 
The importance of rigid imide ring system for hypolipidemic activity was determined. 
Therefore, two series of cyclic imides; diphenimide (8) and its open acyclic imides; 
dibenzimide (9), and succimide (10), and diacetimide (11) were examined for hypolipidemic 
activity in mice.  
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It was shown that the rigid imide ring system was not necessary for hypercholesterolemia 
activity. However, the cyclic imide's structure was a necessary requirement for a good 
hypotriglyceridemic activity (Voorstad. et.al. 1985).  
A series of nitrogen substituted N-butan-3-one derivatives of cyclic imides; such as 
phthalimides (12), o-benzosulphimide (13), 1,8-naphthalimide (14), and diphinimide (15) 
were prepared (Chapman JM. et al. 1990). 
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Molecular modeling programs were used to compare the 3D structures of the some  
derivatives  of some cyclic imides with the already known  Clofibrate (2) (ethyl ester of 2,2-
dimethylphenoxyacetic acid), These overlays were made with the aid of computer Accelry’s 
soft wares at the Computer laboratory, Faculty of Pharmacy, KAU, KSA.  
The Changes in the structure of phthalimide involving the imide's ring system led to the 
preparation of new compounds with potent and significant antihyperlipidemic effect; this is 
due to the good efficacy of their binding to the fatty acid receptor sites (Hall IH et al. 1986). 
The promising hypolipidemic activity of certain cyclic imides derivatives in experimental 
animals strongly potentiate and recommend more researches in this area (El-Zahabi MA et 
al. 2010). Moreover; the newly synthesized compounds may be useful in the prevention of 
cardiovascular disease in a growing population suffering from lifestyle-induced metabolic 
dysfunction (Project 040/1428 H, Gad L M. et al.;funded by the Deanship of Scientific 
Research, King Abdulaziz University, KAU, Jeddah, KSA). 
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